Elevated levels of Src kinase activity have been reported in a number of human cancers, including colon and breast cancer. We have analysed four human breast tumor cell lines that exhibit high levels of Src kinase activity, and have determined that these cell lines also exhibit a high level of a phosphotyrosine phosphatase activity that recognizes the Src carboxy-terminal PTyr530 negative regulatory site. Total Src kinase activity in these cell lines is elevated as much as 30-fold over activity in normal control cells and speci®c activity is elevated as much as 5.6-fold. When the breast tumor cells were grown in the presence of the tyrosine phosphatase inhibitor vanadate, Src kinase activity was reduced in all four breast tumor cell lines, suggesting that Src was being activated by a phosphatase which could recognize the Tyr530 negative regulatory site. In fractionated cell extracts from the breast tumor cells, we found elevated levels of a membrane associated tyrosine phosphatase activity that preferentially dephosphorylated a Src family carboxy-terminal phosphopeptide containing the regulatory tyrosine 530 site. Src was hypophosphorylated in vivo at tyrosine 530 in at least two of the tumor cell lines, further suggesting that Src was being activated by a phosphatase in these cells. In preliminary immunoprecipitation and antibody depletion experiments, we were unable to correlate the major portion of this phosphatase activity with several known phosphatases.
Introduction
The product of the human c-src protooncogene is a tyrosine kinase which has been reported to be activated in a number of human cancers including colon cancer and breast cancer (Cartwright et al., 1989 (Cartwright et al., , 1990 Jacobs and Rubsamen, 1983; Luttrell et al., 1994; Muthuswamy et al., 1994; Ottenho-Kal et al., 1992; Rosen et al., 1986; Talamonti et al., 1993) . Recently, several lines of evidence have suggested that Src kinase activity might be involved in the causation or development of mammary tumors. Src tyrosine kinase activity has been found to be present at increased levels in both human primary breast tumor cells and in breast tumor cell lines (Jacobs and Rubsamen, 1983; Ottenho-Kal et al., 1992; Rosen et al., 1986; Pang et al., in preparation) . Enzyme activity appears to be enhanced between four-and 25-fold in approximately one third of the primary mammary carcinomas examined and in cell lines. It is highly possible that aberrant activation of Src kinase plays an important role in the genesis or maintenance of breast cancer in humans, since Src activity has been correlated with tumorigenicity of human breast tumors (Ottenho-Kal et al., 1992) , and has been found to be a requirement for the induction of mammary tumors by transgenic expression of polyoma virus middle-T antigen or human cneu/HER2 in a mouse model system (Guy et al., 1994) .
Src has also been shown to associate in vitro and in vivo with activated forms of the epidermal growth factor receptor (EGFR) and Neu/HER2 receptor (Luttrell et al., 1994; Maa et al., 1995; Oude Weernink et al., 1994; Stover et al., 1995) , both of which have been correlated with poor prognosis in the 20 ± 30% of breast cancer cases in which these receptors are found to be ampli®ed or overexpressed (Berger et al., 1988; Kraus et al., 1993; Slamon et al., 1987 Slamon et al., , 1989 Varley et al., 1987) . Overexpression of the neu proto-oncogene in the mammary glands of transgenic mice has been shown to cause tumors, following a latency period of 200 ± 400 days (Guy et al., 1992) . Src speci®c activity is elevated in these tumors, relative to the adjacent normal epithelial tissue and the activation of Src in these cells correlates with its ability to bind to the activated Neu receptor Muthuswamy et al., 1994) . Expression of an activated Y527F mutant form of chicken Src alone in the mammary glands of transgenic mice caused hyperplasia but was not sucient for the induction of mammary tumors (Webster et al., 1995) . Murine ®broblasts overexpressing chicken Src have been shown to undergo increased DNA synthesis in response to EGF stimulation (Luttrell et al., 1988) . Similarly, in a human breast cancer cell line transfected with the EGF receptor and overexpressing it, Src activity was enhanced following stimulation by EGF (Oude Weernink et al., 1994) . Furthermore, Src has been found in association with the EGF receptor in immune complexes from breast tumor cells (Luttrell et al., 1994) . These data suggest that Src may play a role in some breast cancers through a signalling mechanism involving the EGF or Neu receptor.
Approximately 30 ± 40% of human breast tumor cell lines that we have studied exhibit levels of Src kinase activity that are elevated up to 30-fold relative to normal breast epithelial cells and ®broblasts, with Src kinase speci®c activities increased as much as 5.6-fold, and levels of Src protein elevated as much as 4 ± 5-fold (Pang et. al., in preparation) . In the current study we have examined in more detail four of the breast tumor cell lines that exhibited increased levels of Src kinase activity in an eort to clarify certain possible mechanisms of Src kinase activation in breast cancers. Our studies indicate that markedly elevated levels (up to 10-fold) of a phosphotyrosine phosphatase (PTPase) activity capable of dephosphorylating the negative regulatory COOH-terminal Tyr530 residue of human Src was present in these breast tumor cell lines. It is likely that elevation of this PTPase activity is contributing at least in part to the presence of higher levels of Src kinase activity in the breast tumor cell lines examined. In preliminary immunoprecipitation and antibody depletion experiments, we were unable to correlate the major portion of phosphatase activity we observed against a phosphorylated Src carboxy-terminal peptide with that of any of several candidate phosphatases, including SH-PTP1, PTP1B, SH-PTP2, PTPalpha and CDC25B. In initial chromatographic separation of phosphatase activities from the tumor cell lysates we have been able to separate a major peak of activity against the Tyr530-containing phosphopeptide from fractions containing SH-PTP1, PTPalpha, CDC25B or the phosphatase LAR. Our results suggest that it is likely that the phosphatase activity observed in these breast tumor cell lines is greatly facilitating activation of Src in the breast tumor lines tested.
Results

Levels of Src protein and kinase activity in breast tumor cell lines
Src tyrosine kinase activity has been shown to be elevated in human primary breast tumors and breast tumor cell lines (Jacobs and Rubsamen, 1983, Ottenho-Kal et al., 1992; Rosen et al., 1986; Pang et al., in preparation) , and in murine breast tumors induced after expression of a polyoma middle-T or human Neu transgene (Guy et al., 1994; Muthuswamy and Muller, 1995; Muthuswamy et al., 1994) . In order to investigate the possible involvement of Src and mechanisms of Src kinase activation in human breast cancer we examined Src kinase activity and protein levels in four breast tumor cell lines (SK-BR-3, BT-483, MDA-MB-435S and MDA-MB-468) that were found to exhibit elevated levels of Src kinase activity in a larger screen of ®fteen breast tumor cell lines (Pang et al., in preparation) .
To determine whether Src tyrosine kinase activity was speci®cally elevated in the breast tumor cell lines, relative to control foreskin ®broblast (HFF) cells and a normal breast epithelial cell line (Hs-578Bst), Src was immunoprecipitated using stringent conditions from the four tumor lines and from control cells, using an excess of Src kinase speci®c Mab 327, and kinase assays were performed on the immunoprecipitates using acid denatured enolase as an exogenous substrate. Figure 1 depicts a result which is representative of a number of such experiments. In Figure 1a and c, the ability of Src to both autophosphorylate and to phosphorylate enolase can be seen to be greatly elevated in the tumor cell lines tested, relative to HFF and normal breast epithelial cells (Hs-578Bst). Total Src kinase activity was estimated by densitometric scan of the autoradiogram, and of other exposures, and was determined to be as high as 30 times that present in the normal control cells (Table  1a) . As Src activity is regulated to a major extent by phosphorylation on tyrosine residues, we sought to determine whether inhibition of tyrosine phosphatase activity in the breast tumor cell lines would aect Src kinase activity. Accordingly, plates of cells which had been set up in duplicate to those used for the Src kinase assays shown in Figure 1a were grown in the presence of the tyrosine phosphatase inhibitor sodium orthovanadate for 6 h prior to harvesting and assaying for Src kinase activity (Figure 1b) . Interestingly, Src kinase activity appeared to be reduced in the tumor cell lines which were grown in the presence of sodium orthovanadate. In at least three of these lines ( Figure  1b , lanes 7,9 and 10) Src activity was reduced to levels roughly equivalent to those seen in HFF cells (lane 6). In the fourth line (BT-483), Src activity was clearly reduced under conditions of phosphatase inhibition (compare lanes 3 and 8), but not to the same extent as seen in the other three cell lines. These results suggested to us that inhibition of tyrosine phosphatase activity could reduce Src kinase activity by preventing or reducing dephosphorylation of the negative regulatory Tyr 530 site.
Src protein levels in the breast tumor cells were determined using whole cell lysates prepared from subcon¯uent cell cultures containing roughly equal numbers of cells. Figure 2 again illustrates the result of a representative experiment. 50 mg or 200 mg of protein from the tumor or normal cell lysates were separated on a 9% SDS ± PAGE gel and transferred to nitrocellulose. The samples were subjected to immunoblot analysis using the Src-speci®c Mab327 monoclonal antibody. As depicted in Figure 2 , the tumor cell lines produced levels of Src protein that were higher than the level in normal HFF cells. Cells grown in the presence of vanadate showed similar relative levels of Src protein (data not shown). When these levels were quantitated by densitometer scan they were found to vary from 1.2 times the amount of Src (MDA-MB-468) to 5.6 times the amount (BT-483) (Table 1a) . Src protein levels were found to be the same in both control HFF cells and a normal breast epithelial cell line (Hs-578Bst) (data not shown).
Estimates of Src kinase speci®c activity in the tumor and control cell lines were obtained by quantitating the representative phosphorylation levels of Src and enolase from Figure 1a by densitometric scanning and normalizing to the amounts of Src protein in each cell line, as determined by Western blot analysis using Mab327. Src speci®c activity was elevated two-to ®vefold in these tumor cell lines, relative to normal control cells. In order to obtain a second quantitative measurement of Src kinase activity in these cell lines, Src kinase activity from Elevated PTPase and Src kinase in breast tumor cells C Egan et al these lines was also tested by its ability to phosphorylate two peptide substrates, the Cdc2(6-20) peptide, which has been previously shown to be an excellent substrate for Src family kinases (Litwin et al., 1991; Uckun et al., 1996; Yuan et al., 1995) and the`Src optimal peptide' (AEEEIYGE-FEAKKKK) which has been shown to be an optimal substrate for Src kinase (Songyang et al., 1995) . The relative amounts of phosphate incorporation in the peptide assays were measured by scintillation counting (Table 1 ) and the activity of Src in each cell line was again compared to HFF cells to determine the fold increase in activity, and the increase in speci®c activity. The activity of Src against these substrates as well is elevated in all of the tumor cells relative to the control HFF cells, and agrees well with the autophosphorylation and enolase results. Taken together, our data show that increases in total Src kinase activity in the lysates of the breast tumor cell lines result from an elevation in the levels of Src kinase speci®c activity, and in some cases also from increases in Src protein levels. Preferential dephosphorylation of a Src peptide substrate in breast tumor cell lines
As the activity of Src is regulated to a large extent by phosphorylation and dephosphorylation of the COOHterminal negative regulatory Tyr 530 site Cartwright et al., 1987; Kmiecik and Shalloway, 1987; Tanaka et al., 1990) , and as Src appeared to be less active when immunoprecipitated from cells grown in the presence of phosphatase inhibitors (Figure 1 ), we hypothesized that the tumor cell lines might contain a phosphatase activity that could speci®cally dephosphorylate Src at the tyrosine 530 regulatory site, thus having the potential to activate the enzyme. As a preliminary approach, we compared the ability of extracts from normal breast epithelial and HFF cells to extracts from the four breast tumor cell lines to dephosphorylate in vitro a Src family member Fyncarboxy terminal peptide (FCP) (residues 503 ± 537), which closely resembles the Src carboxy terminus around the tyrosine 530 site (O'Connor et al., 1995) .
We also compared the lysates in their ability to dephosphorylate an unrelated peptide (Cdc2[6-20]) or a non-speci®c substrate (Poly-Glu-Tyr [PGT]) as controls. Peptides were radiolabeled in vitro using CSK (C-terminal Src Kinase) or the Src mutant CST-1 and 32 P-gamma ATP as described in Materials and methods, and phosphatase assays were performed using cell lysates which had been fractionated into membrane-containing and cytoplasmic components. Assays were carried out over a 15 min period with aliquots being removed to stop the reactions at 3 min intervals. The amount of radiolabel remaining on the peptides was determined by scintillation counting. The ratio of the number of counts remaining at a given time point to the counts present at the zero time point was determined to give the`percent phosphorylation' of the peptide population as a whole, at that time point. The results are summarized in Figure 3a Figure 3b clearly indicates that the membrane fractions from the four breast tumor cell lines, but not the normal cells, contain markedly elevated levels of PTPase activity capable of dephosphorylating the FCP peptide, and that this phosphatase activity is largely absent in the cytoplasmic fractions of these cells (Figure 3a ). This phosphatase activity is reasonably speci®c, as the membrane fractions containing this activity do not dephosphorylate the non-related (Songyang et al., 1995) were obtained in an indepdent experiment Figure 2 Western blot analysis of Src protein levels in human breast tumor cell lines. 50 mg (lanes 1 ± 5) or 200 mg (lanes 6,7) per lane of whole cell lysates from normal HFF cells (lanes 2 and 7) or breast tumor cell lines (lanes 1, 3 ± 6) were probed with the anti-Src monoclonal 327 antibody, followed by ECL detection Cdc2(6-20) peptide (Figure 3d ) and in most cases show lesser dephosphorylation of a non-speci®c Poly-GluTyr substrate (Figure 3f ). The rates of dephosphorylation of the FCP peptide over the ®rst 3 min of the reaction are 4.8 ± 9.6 times higher in the breast tumor cell extracts than in the normal breast epithelial or HFF cell extracts (Table 2) , and these rates are again higher than they are against the non-speci®c PGT substrate in these cell extracts. A range of concentrations of each of the three peptide substrates (10 mM to P-orthophosphate. The cells were lysed and equal amounts of protein from the lysates were immunoprecipitated with an excess of Mab 327, and peptide mapping experiments were performed on these immunoprecipitated Src molecules, using CNBr cleavage. The immunoprecipitated proteins were separated on two 9% gels, with 25% of the sample on one gel to quantitate the levels of Src protein in the immunoprecipitates, and the other 75% on a separate gel to use as preparative material for cyanogen bromide cleavage of the Src proteins. The preparative gel was exposed wet to ®lm for 1 h to visualize the radioactively labeled Src bands, which appeared to be of similar intensity, signifying roughly equal amounts of orthophosphate incorporation (Figure 4a ). Immunoblotting of samples using Mab327 and detection by enhanced chemiluminescence (ECL), revealed that the SK-BR-3 cell line contained somewhat higher levels of Src (about 2.6-fold) than were present in HFF cells (Figure 4b ). Bands were visualized by ECL, with detection times being too short to allow the endogenous 32 P to in¯uence the signal. The Src protein bands were cut from the preparative gel and subjected to CNBr cleavage as described in Materials and methods. The cleavage products were separated on a 22% SDS ± PAGE gel, and visualized by autoradiography ( Figure  4c ). The relative intensities of the bands in Figure 4a , b and c were quantitated by phosphorimager analysis and these relative values appear below their respective lanes (Figure 4, bottom) . The intensity of the signal in the tyrosine 530 band is much lower in SK-BR-3 than in HFF cells (Figure 4c ). When the intensity of the tyrosine 530 signal is normalized to the amount of protein present, it can be seen that Src in the SK-BR-3 cells is phosphorylated only to 25% of the extent on tyrosine 530 that it is in the HFF cells. In the same (Figure 4b ). This preparative material was digested with CNBr and the digestion products were separated on a 22% SDS ± PAGE gel. The intensity of the phosphorylated Tyr 530 band from Src protein isolated from BT-483 cells was slightly reduced relative to HFF cells (77%) (Figure 4c and d) and when this value was normalized to the ®vefold excess amount of Src protein immunoprecipitated from the BT-483 cells, it was apparent that Src from the BT-483 cells was phosphorylated only to 15% the extent on Tyr 530 as Src from the control HFF cells. Thus Src proteins in both SK-BR-3 and BT-483 breast tumor cell lines are hypophosphorylated in vivo at the negative regulatory Tyr 530 site relative to control HFF cells. We noted that there was no increase in phosphorylation of Tyr419 (the Src autophosphorylation site associated with increased Src kinase activity) accompanying reduction of phosphorylation at Tyr530, as might have been expected. A similar observation has been reported by Zheng et al., (1992) who found that overexpression of PTPalpha in rat ®broblasts resulted in dephosphorylation of Src kinase at Tyr530 and activation of enzyme activity, without phosphorylation of the activating Tyr419 site.
Preliminary analysis of some known tyrosine phosphatases in breast tumor cell lines Several previous reports have suggested possible roles for speci®c PTPases in the development of breast and other cancers (den Hertog et al., 1993; Elson and Leder, 1995; Galaktionov et al., 1995; Pallen, 1993; Shen et al., 1991; Tomic et al., 1995; Zhai et al., 1993) , including SH-PTP1, PTP1B, SH-PTP2, PTPalpha, LAR and Cdc25B. We examined the expression of these phosphatases in the four breast tumor cell lines studied here, which we had shown to have higher levels of Src-speci®c phosphatase activity. Whole cell lysates were made from control HFF or Hs-578Bst cells, or from the tumor lines SK-BR-3, BT-483, MDA-MB-435S and MDA-MB-468, and equal amounts of protein from these lysates were separated on 9% SDS ± PAGE gels. The separated proteins were then transferred to nitrocellulose and immunoblotted with polyclonal antibodies to human SH-PTP1, PTP1B, SH-PTP2, PTPalpha, LAR or Cdc25B, followed by ECL detection (data not shown). Some of these phosphatases were found to be expressed at higher levels in some of the breast tumor cell lines, but none were found to be elevated in all four of the lines with increased Src-speci®c phosphatase activity. SH-PTP2 and LAR were expressed in the tumour cells at levels similar to control cells, but SH-PTP1, PTP1B, PTPalpha and Cdc25B expression was detectable only in some and not all of the four tumour cell lines. Immunoprecipitation and antibody depletion experiments have failed to show activity of the above phosphatases against the Tyr530 phosphopeptide (data not shown). A preliminary anion exchange chromatographic separation of phosphatase activities from the four tumour cell lines has shown a similar elution pro®le for each cell line with a major initial peak of activity against the Tyr530-containing phosphopeptide followed in some cases by other major or minor peaks of activity. Western blotting of column fractions using antibodies directed against the above phosphatases has demonstrated that LAR, Cdc25B, SH-PTP1 and PTPalpha elute at higher salt concentrations than the major peak of anti-Tyr530 phosphatase activity, although SH-PTP1 and Cdc25B coelute with secondary peaks of activity in at least two of the tumor cell lines (data not shown).
Discussion
We have investigated the mechanism of activation of Src in four human breast tumor cell lines in which total Src kinase activity is activated as much as 30-fold relative to normal human breast epithelial and normal foreskin ®broblast cells. The molecular mechanisms which are involved in the transformation of normal breast epithelial cells to tumor cells are only just beginning to be understood and are likely to be complicated, but a number of studies have reported high Src activity in up to as many as 70% of primary breast carcinomas and cell lines tested (Galaktionov et al., 1995; Jacobs and Rubsamen, 1983; Ottenho-Kal et al., 1992; Rosen et al., 1986) . This suggests that Src kinase may play a very important biological role in the development or progression of the disease. In addition, we have recently obtained strong evidence from in vitro cell transformation studies that con®rms this potential role of Src. We have found that three-to fourfold overexpression of human c-Src in stably transfected human breast epithelial cells confers transformation and anchorage-independent growth on these cells as measured by the ability to form colonies in soft agar (Achari et al., in preparation) .
In the four breast tumor cell lines which we have reported on in this study, the total Src kinase activity is elevated due to increased Src kinase speci®c activity and increased Src protein levels, although the level of Src protein in the tumor cell lines was somewhat variable. Both of these factors may contribute to the biological eect of Src in breast cancer cells in an additive or synergistic manner. We were interested in determining how Src kinase speci®c activity was increased in the breast tumor cell lines and we have demonstrated that these breast tumor cell lines contain much higher levels than normal breast epithelial or foreskin ®broblast cells of a tyrosine phosphatase activity associated with the particulate membranecontaining fraction of the cells which can dephosphorylate a Src-like peptide containing the regulatory tyrosine 530 residue, with higher eciency than unrelated peptides. In at least three of the tumor cell lines, addition of the phosphatase inhibitor sodium vanadate to the growth medium 6 h before lysis resulted in a reduction of Src kinase speci®c activity to the levels seen in the normal control cells. The fourth tumor cell line showed Src kinase activity that was reduced but to a lesser extent under these conditions. These results further suggested that Src may have increased activity in breast tumor cells as the result of the action of a phosphatase. We have also shown that Src in these tumor cells is hypophosphorylated in vivo on tyrosine 530 in comparison to HFF cells. This suggests that preferential dephosphorylation of tyrosine 530 by what may be a speci®c tyrosine phosphatase, is likely to be involved in the activation of Src kinase in breast cancer cells.
Recently, association between Src and Neu and/or EGF receptors in murine and human breast tumors or tumor cell lines has been reported, and the data suggest that Src may be involved in signal transduction pathways that involve these receptors in breast cancer cells (Luttrell et al., 1994; Maa et al., 1995; Muthuswamy and Muller, 1995; Muthuswamy et al., 1994; Oude Weernink et al., 1994) . At least two of the breast tumor cell lines that we have examined (SK-BR-3 and MDA-MB-468) have been previously shown to have overexpressed and/or ampli®ed Neu or EGF receptors (Janes et al., 1994; Kraus et al., 1987) . Because Src acts downstream of these receptors (Roche et al., 1995; Wilson et al., 1989) , it would be expected that the action of a Src carboxy-terminal phosphatase would contribute to and augment the activation of Src kinase, regardless of the status of the Neu or EGF receptors in these cells. However it is likely that an additive or synergistic eect on activation of Src kinase activity might be seen when high Src carboxy-terminal phosphatase activity and overexpressed receptor tyrosine kinases are present together.
There is also other suggestive evidence that some phosphotyrosyl phosphatases may potentially play a role in the etiology of breast cancer and the transformation of other cell types through an interaction with Src and/or EGF receptor members. It is not clear, however if any of these phosphatases are involved in Src activation in breast tumor cells. For example, SH-PTP1 and SH-PTP2 can associate in vitro and in vivo with the EGF receptor (Tomic et al., 1995) , and SH-PTP2 has been detected in association with Src in a human colon carcinoma cell line (Peng and Cartwright, 1995) , although biological eects of these associations have not been demonstrated. In addition, SH-PTP1 is capable of dephosphorylating Src in vitro at Tyr530 and there is a positive correlation between the expression of SH-PTP1 and Src kinase activity in vivo in mouse thymocytes (Somani et al., 1997) . The phosphatases LAR and PTP1B have been reported to be overexpressed in human breast epithelial cells transformed with an activated rat Neu receptor (Zhai et al., 1993) . The human phosphatase Cdc25B has been found to be overexpressed in 32% of a panel of human primary breast tumor samples (Galaktionov et al., 1995) . The murine transmembrane phosphotyrosyl phosphatase PTPepsilon is expressed at increased levels in tumor tissue from transgenic mice bearing ras or neu induced mammary tumors, but not myc or int-2 induced tumors (Elson and Leder, 1995) . PTPalpha, which is the human homolog of PTPepsilon, is capable of transforming rat embryo ®broblasts when overexpressed in transfected cells and transformation has been correlated with a three-to six-fold increase in Src kinase activity, accompanied by preferential dephosphorylation of Src at the carboxyl terminal tyrosine 530 site (Zheng et al., 1992) . Similarly, overexpression of PTPalpha in transfected murine embryonal carcinoma (EC) cells results in increased Src kinase speci®c activity (den Hertog et al., 1993) . Taken together, these studies suggest that PTP's may play a role in receptor signalling mechanisms and possibly in Src activation in mammary carcinomas and other cell types. It is important to note, however, that although elevated PTPase activity has been suggested to activate Src in other tissues, this is the ®rst demonstration of a PTPase activity in breast tumor cells that recognizes the Src-family C-terminal P-Tyr containing regulatory domain as a substrate. The data presented here suggest the existence of such a phosphatase or phosphatases which can dephosphorylate the tyrosine 530 residues of Src and activate it in breast cancer cells.
In an attempt to identify the phosphatase responsible for the activity we observed, we used antibodies against six phosphatases; SH-PTP1, PTP1B, SH-PTP2, PTPalpha, LAR and CDC25B, which we thought might be likely candidates to interact with Src in breast cancer cells. We found some of these to be overexpressed in some of the tumor cell lines but none were overexpressed in all of the tumor cell lines, and some were not detectible in some of the tumor cell lines. Preliminary results from the chromatographic separation of PTP activities present in the breast tumor cell lysates, followed by Western blotting of column fractions using antibodies directed against the above phosphatases, has demonstrated that SH-PTP1, PTPalpha, LAR and Cdc25B elute in fractions distal to the major peak of anti-Tyr530 phosphatase activity, although SH-PTP1 and Cdc25B co-elute with secondary peaks of activity in fractions from two of the breast tumor cell lines. This suggests that the Srcspeci®c phosphatase activity present in the breast cancer cell lines may be largely due to a phosphatase which is as yet unidenti®ed. This is not, perhaps surprising, considering that the number of phosphotyrosine phosphatases has been suggested to number in the hundreds, and may be as numerous and as varied as the tyrosine kinases (Charbonneau and Tonks, 1992) . We are attempting to identify the phosphatase(s) involved in Src activation in breast tumor cells, and to further investigate its role in human breast cancer.
Materials and methods
Cell lines and culture
The human breast cancer cell lines SK-BR-3, BT-483, MDA-MB-435S and MDA-MB-468 and the normal human breast epithelial cell line Hs-578Bst were obtained from the American Type Culture Collection (Rockville Maryland, USA). Human foreskin ®broblast cells (HFF cells) were the gift of W Hwang (Foothills Hospital, Calgary, Canada) . SRA cells were derived from chick embryo ®broblasts infected with Schmidt-Ruppin A-Rous sarcoma virus. Cells were cultured in DMEM, supplemented with 4.5 g/L glucose, 10% foetal bovine serum, L-glutamine, 100 U/ml penicillin G and 100 mg/ml streptomycin. For some experiments, 50 mM Sodium Orthovanadate was added to the growth medium 6 h prior to harvesting. Cells were grown at 378C in 5% CO 2 and were passaged using 0.1% trypsin for detachment.
Phosphorylation of peptide substrates
Fyn carboxy-terminal peptide (FCP), consisting of residues 503 ± 537 of the human Fyn carboxy terminus (O'Connor et al., 1995), Cdc2(6-20) and poly-glu-tyr (PGT) were labeled in vitro using gamma-ATP as follows. Labeling reactions were done in 115 ml aliquots of 50 mM HEPES buer (pH 7.0), 2.0 mM MnCl 2 , 150 mM NaCl, 1.0 mM DTT, 0.02 mM ATP, 200 mCi gammaATP, 0.83 mM of the appropriate peptide. Reactions were initiated by adding 75 ng of puri®ed CSK (cSrc kinase) to the FCP reactions or 6.4 mg of puri®ed CST-1 (an activated E381G mutant of Src) (2) to the Cdc2(6-20) or PGT reactions and these were carried out at 308C for 2 h. Peptides were precipitated in 20% TCA using 4 mg BSA as carrier, centrifuged and precipitated pellets were washed with 5% TCA followed by ether, and resuspended in 1 ml of 50 mM Tris pH 7.0 by sonicating.
Cell fractionation
Sub-con¯uent plates of cells were rinsed with cold PBS, and the cells harvested by scraping the plates, resuspending the cells in cold PBS and centrifuging 220 g for 10 min. Cell pellets were resuspended in 1 ml cold Homogenization Buer (50 mM HEPES pH 7.2, 5.0 mM EGTA, 5.0 mM EDTA, 20 mM NaFl, 5.0 mM NaKTartrate, 1.0 mM Tetramisole, 0.1% b-Mercaptoethanol, 2.0 mg/ml Leupeptin, 1.0 mM Benzamidine and 0.1 mM PMSF) and homogenized manually on ice using a Dounce Homogenizer. Sucrose was added to 250 mM and the lysates were centrifuged at 1000 g for 10 min to pellet unbroken cells and nucleii. Supernatants were then centrifuged at 87 900 g at 408C for 35 min to pellet membranes. The supernatants were removed, and the membrane pellets resuspended in 250 ml of homogenization buer and centrifuged again. The second supernatant was combined with the ®rst to give the soluble fraction of the cell lysates and the membrane pellet was resuspended in 250 ml of PTP Lysis Buer (50 mM HEPES pH 7.2, 1% Triton-X 100, 5.0 mM EGTA, 5.0 mM EDTA, 20 mM NaF, 5.0 mM NaKTartrate, 1.0 mM Tetramisole, 0.1% b-Mercaptoethanol, 2.0 mg/ml Leupeptin, 100 mM Benzamidine and 0.1 mM PMSF), and incubated on ice for 1 hour to solubilize the membrane proteins. This was again centrifuged at 87 900 g at 48C for 35 min and the supernatants constituting the membrane fraction were saved. Protein concentrations for both the soluble and membrane fractions were determined by Bradford assay, and the cell fractions were stored at 7808C in 10% glycerol until use.
Phosphatase assays
Phosphatase assay reactions contained 20 mM of the appropriate peptide and 2.5 mg of soluble or membrane cell fraction in PTP Assay Buer (50 mM HEPES pH 7.2, 0.1% Triton-X 100, 5.0 mM EDTA, 5.0 mM EGTA, 20 mM NaFl, 5.0 mM NaKTartrate, 1.0 mM Tetramisole, 1.0 mM DTT, 2.0 mg/ml Leupeptin, 1.0 mM Benzamidine and 0.1 mM PMSF) in a ®nal volume of 175 ml. These were reacted at 308C for up to 15 min with 25 ml aliquots being removed and stopped at 3 min time intervals. Reactions were stopped in 20 ml of 50% acetic acid, and spotted on phosphocellulose paper. The phosphocellulose was washed ®ve times in 0.5% phosphoric acid to remove free phosphate, washed once in acetone, dried and counted in scintillant.
32 P-orthophosphate labeling of cells DMEM was removed from sub-con¯uent plates of cells which were then washed with phosphate-free MEM (supplemented with 4% DMEM containing 10% FCS, and 1% dialysed FBS) and incubated in supplemented phosphate-free MEM for 45 min. This medium was then removed and replaced with supplemented phosphate-free MEM containing 0.275 mCi/ml [ 32 P]-orthophosphate, and the cells were incubated at 378C for 18 h prior to harvesting.
Preparation of cell lysates
Plates were washed three times with cold PBS and cells were harvested by scraping and resuspending in RIPA Buer (25 mM Tris pH 7.2, 0.1% SDS, 1% Triton-X 100, 1% Sodium Deoxycholate, 150 mM NaCl and 1 mM EDTA) freshly supplemented with 0.1 mg/ml Leupeptin, 7.5 mg/ml pNPP and 1.0 mM Sodium Orthovanadate. Lysates were clari®ed by centrifugation, protein quantitation was done by Bradford assay, and lysates were either used immediately or stored at 7808C. Lysates to be run directly on SDS-PAGE gels were mixed with an equal volume of 26SDS-PAGE Sample Buer.
Immunoprecipitations
Src protein was immunoprecipitated from cell lysates using an excess of the Src speci®c monoclonal antibody Mab 327 (1.5 mg antibody/100 mg cell extract) (gift of J Brugge) and 30 ml of 50% Protein A/Protein G (1 : 1) in RIPA Buer. The tyrosine phosphatases SH-PTP1, PTP1B, SH-PTP2, PTPalpha, LAR and Cdc25B were immunoprecipitated using an excess of commercially prepared antibodies from Upstate Biotechnology (Lake Placid, NY, USA) or Santa Cruz Biotechnology (Santa Cruz, CA, USA). Immunoprecipitations were mixed at 48C on an end over end rotator for 2 h, then washed three times with supplemented RIPA Buer and either suspended in 16Sample Buer for SDS ± PAGE or prepared for kinase or phosphatase assays.
Kinase assays
For Src and Enolase kinase assays, immunoprecipitated pellets containing Src protein were washed with 0.5 ml Src Kinase Buer (20 mM Tris pH 7.2, 5.0 mM MnCl 2 ) and incubated on ice 5 min. The pellets were then centrifuged and resuspended in 30 ml of Src Kinase Buer. 2.0 ml of 2.5 mg/ul prepared enolase and 10 mCi of gamma-ATP were added and the reaction was incubated at room temperature for 10 min. Reactions were stopped by adding an equal volume of 26SDS ± PAGE sample buer and boiling for 3 ± 5 min. Samples were run on 8% SDS ± PAGE gels and analysed by autoradiography. Quantitation of band intensity was done by densitometer scan of the autoradiogram of the gel after appropriate exposures. To assay Src kinase activity against the Cdc2(6-20) peptide (Uckun et al., 1996; Yuan et al., 1995) and the Src optimal peptide (AEEEIYGEFEAKKKK) (Songyang et al., 1995) , immunoprecipitates containing Src protein were resuspended in 50 ml of Cdc2 Assay Buer (50 mM Tris pH 7.0, 0.05 mM Sodium Orthovanadate, 3.0 mM pNPP, 50 mM MgCl 2 , 5 mM MnCl 2 , 0.1% NP40, 0.08 mM Cdc2(6-20) peptide, 0.1 mM ATP and 0.02 mCi/ul 32 P gamma-ATP). Reactions were allowed to continue at 308C for 20 min and then the Cdc2(6-20) peptide reactions were stopped by the addition of 25 ml of 50% acetic acid. The Src optimal peptide reactions were stopped by adding 20 ml of 70% trichloroacetic acid, 10 ml of 30 mg/ml bovine serum albumin, precipitating on ice 5 min and spinning to remove the precipitated material. 60 ml of the supernatant was spotted onto phosphocellulose paper, which was then washed four times with 0.5% phosphoric acid to remove free ATP, rinsed with acetone, dried and counted in scintillant.
Cyanogen bromide cleavage of Src protein
Immunoprecipitated Src proteins from 32 P-orthophosphate labeled cell extracts were separated using 9% SDS ± PAGE Elevated PTPase and Src kinase in breast tumor cells C Egan et al and the gel was exposed to ®lm to detect phosphorylated Src protein. The radioactive bands were cut from the gels and the proteins subjected to cleavage with cyanogen bromide as previously described (Jove et al., 1987) . Cleavage products were separated on 22% SDS ± PAGE gels which were then dried and the bands visualized by autoradiography. Phosphorimager analysis of the cleavage products was used for quantitative purposes.
Western blotting
Proteins to be analysed by Western Blot were separated on 8% or 9% SDS ± PAGE gels followed by transfer to nitrocellulose overnight at 100 mA. Blots were rinsed brie¯y in TBS-T (20 mM Tris pH 7.6, 137 mM NaCl and 0.1% Tween-20), then blocked in TBS-T +3% BSA for 1 h at room temperature. Blots were then washed with TBS-T and incubated with the appropriate primary antibody diluted 1/1000 in TBS-T +3% BSA. Anti-Src and antiphosphotyrosine phosphatase antibodies used were the same as those described for immunoprecipitations, and anti-phosphotyrosine antibodies were purchased from Upstate Biotechnology. Incubations were carried out for 1 h at room temperature. The blots were washed again in TBS-T and incubated with an appropriate anti-mouse or anti-rabbit antibody conjugated to horseradish peroxidase in TBS-T+3% BSA. Following a ®nal wash with TBS-T the proteins were visualized by exposure to ®lm following chemiluminescence detection using the appropriate reagents from Amersham. Quantitation of Src bands was by either densitometer scan or by phosphorimager analysis.
